1 Followers
24 Following
sagarj1030

Healthcare Outlook

Trending Updates About Healthcare, Medical Devices, Pharmaceutical etc.

Precision Medicine Diagnostics Market Share to See Modest Growth Through 2026

Precision medicine aims to alter the treatments based on individual characteristics, including differences in genetics, environment, and lifestyle. It has the potential to transform the delivery of care for a variety of diseases. Precision medicine implicate the application of panomic analysis and systems biology to inspect the cause of an individual patient's diseased condition at the molecular level and then to apply targeted treatments to address that individual patient's disease. Precision medicine aims to make medication and medical practices efficient and cost effective. By using the precision medicine, doctors recognize genetic makeup of the subject, which helps doctors to prescribe the right drug with appropriate dose.

 

Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/2422

 

Precision Medicine Diagnostics Market- Drivers

 

Precision medicine diagnostics market is expected to expand at rapid pace in near future, owing to increasing number of pipeline studies to develop new treatment for cancer. For instance, in January 2016, University of Arkansas initiated the clinical trial for fresh tissue biopsy to study the further advancements in bio-specimens (blood cellular free component, e.g., plasma, serum, tissue, urine), in order to develop precision medicine for lung cancer management and screening (synergy with imaging). Fresh tissue biopsy involves taking a small sample of tissue from the body part for further microscopic examination. The study is estimated to complete in December 2019.

 

Precision Medicine Diagnostics Market- Regional Analysis

 

On the basis of region, the global precision medicine diagnostics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

 

Geographically, North America accounts for the largest share in the global precision medicine diagnostics market, owing to increasing awareness and initiative related to precision medicine in the North America. For instance, in 2015, the U.S Government launched the Precision Medicine Initiative to revolutionize method to improve health and treat disease. The precision medicine initiative will enable health care providers to adapt new treatment and prevention strategies to people’s unique characteristics, including their genome sequence, micro-biome composition, health history, lifestyle, and diet.

 

Precision Medicine Diagnostics Market- Key Players

 

Some of the major players operating in the precision medicine diagnostics market include Intomics, Ferrer Incode, Nanostring Technologies, Inc., Tepnel Pharma Services, Pfizer, Inc., Novartis AG, Teva Pharmaceuticals, Merck & Co., Inc., Qiagen N.V., and Quest Diagnostics.

 

Precision Medicine Diagnostics Market- Taxonomy

 

By Technology:

 

Bioinformatics

Gene Sequencing

Drug Discovery

Precision Molecular Diagnostics

Big Data Analytics

 

By Application:

 

Oncology

Breast cancers

Lung Cancer

Others

CNS

Hematology

Respiratory

Immunology

Others

 

Browse In-Depth Analysis Research Report: https://www.coherentmarketinsights.com/ongoing-insight/precision-medicine-diagnostics-market-2422

 

About Coherent Market Insights:

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

 

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Asia Pacific Newborn Screening Market is Progressing Towards a Strong Growth By 2026

Infants are most vulnerable to diseases such as polio, epilepsy, encephaliphitis, asthma, COPD and other respiratory disease, diarrhea, leukemia, anemia, and other rare diseases that results in substantial economic burden.

 

Newborn screening describes various tests that are performed during first few hours or days of an infant’s life. These tests have the potential of preventing severe health problems and prevents from death. According to American Academy of Pediatrics: 2018, newborn screening and diagnosis are important to ensure that all babies who are deaf or hard of hearing are identified as soon as possible. According to same source, 1 to 3 out of every 1,000 babies born in the U.S. have hearing level outside the typical range. When these babies receive early intervention services, it makes a big difference in their communication and language development in the future.

 

Asia Pacific newborn screening market size was valued at US$ 171.3 million in 2017 and is expected to witness a CAGR of 12.7% during the forecast period (2018 – 2026).

 

Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2546

 

Increasing government initiatives is expected to drive growth of the Asia Pacific newborn screening market

 

Increasing engagement programs by various government healthcare regulatory bodies for newborn screening and its deployment for wider population base are expected to drive growth of the market during the forecast period. For instance, in June 2014, PerkinElmer, a company engaged in the diagnostics, life science research, food, environmental and industrial testing area, entered into an exclusive collaboration with China's National Health and Family Planning Commission (NHFPC) to implement a three-year training program for newborn screening.

 

The National Maternal & Children Health Surveillance Office (NMCHSO) is working with PerkinElmer, to increase availability and adoption of newborn screening in China, particularly via expansion in more rural areas.

 

Asia Pacific Newborn Screening Market- Country Analysis

 

On the basis of country, Asia Pacific newborn screening market is segmented into China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific. China holds the major share due to innovative and new initiatives by government for implementing various newborn screening programs. Currently Congenital Hypothyroidism (CH) and Phenylketonuria (PKU) and hearing loss are included as national wide screening program in China, which is also mandatory for all newborn.

 

Asia Pacific Newborn Screening Market- Competitive Landscape

 

Key players operating in the Asia Pacific newborn screening market include Medtronic plc, Agilent Technologies, Waters Technologies Corporation, AB SCIEX, Bio-Rad Laboratories, Covidien PLC, GE Life Sciences, Masimo Corporation, Natus Medical Inc., PerkinElmer Inc., Trivitron Healthcare Pvt. Ltd., and ZenTech S.A.

 

Detailed Segmentation:

 

Asia Pacific Newborn Screening Market, By Product Type:

Hearing Screening Devices

Mass Spectrometer

Pulse Oximetry

Assay Kits and Reagents

 

Asia Pacific Newborn Screening Market, By Test Type:

Phenylketonuria (PKU)

Critical Congenital Heart Defect (CCHD)

Hearing Screening

Sickle Cell Disease

Maple Syrup Urine Disease (MSUD)

Thyroid Disorder

Biotinidase Deficiency (BTD)

Others

 

Browse In-Depth Analysis Research Report: https://www.coherentmarketinsights.com/market-insight/asia-pacific-newborn-screening-market-2546

 

About Coherent Market Insights:

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

 

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Neuroendocrine Tumor Treatment Market Witness Considerable Growth To 2025

Incidence and prevalence of neuroendocrine tumor is steadily rising, mainly due Multiple endocrine neoplasia type 1 (MEN1), Multiple endocrine neoplasia type 2 (MEN2), Neurofibromatosis type 1 (NF1), Von Hippel-Lindau syndrome (VHL) and Tuberous sclerosis complex (TSC) disease in the U.S. Moreover, based on a study published in the JAMA Oncology Journal, survival rate for all neuroendocrine tumor treatment have improved, especially for distant-stage gastrointestinal neuroendocrine tumor treatment and pancreatic neuroendocrine tumor treatment. This is mainly attributed to improved outcomes of availability of better therapies and early diagnosis. Introduction of new therapies and extended indications for approved drugs would benefit the growth of neuroendocrine tumor treatment market in North America and in turn is expected to significantly fuel growth of the global market. U.S. is the largest market for NET, in terms of revenue. No specific data is available regarding incidence of neuroendocrine tumors in Canada. However, according to the Canadian Cancer Society, 315 people in Canada were diagnosed with endocrine cancers in 2012 and the rate is increasing with early diagnosis and stage migration.

 

Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/129

 

North America neuroendocrine tumor treatment market is expected to dominate the global gastrointestinal NET segment throughout the forecast period. According to Coherent Market Insights analysis, various national universities and small scale pharma-company work on developing various NET drugs and modify clinical approach to treat neuroendocrine tumors. This gives pharma and biotech companies a major opportunity to market their products in the U.S.

 

The global neuroendocrine tumor treatment market was valued at US$ 1,197.3 million in 2015 and is expected to witness a CAGR of 10.5% during the forecast period (2017 – 2025)

 

Innovate drug in pharmaceutical company product pipeline to boost the Neuroendocrine Tumor Treatment Market

 

There are various medical treatment to treat cancer, and targeted therapy is one of the most preferred to treat neuroendocrine tumor treatment. Targeted therapy is a futuristic and highly effective approach for treating cancers and hence, targeted NET therapies are projected to gain significant demand in the near future. Though somatostatins are effective in treating some types of pituitary tumors, regulatory approval for NET is expected to further encourage its research as a combination therapy with targeted drugs.

 

Key Players

 

Key companies covered as a part of this study include Pfizer Inc, Novartis AG, Ispen, Advanced Accelerator Applications, Tarveda Therapeutics, Progenics Pharmaceuticals, Inc., Hutchison Medipharma Limited, Dauntless Pharmaceuticals Inc.and Exelixis, Inc.

 

Detailed Segmentation:

 

Global Neuroendocrine Tumor Treatment Market, By Drug:

Everolimus

Sunitinib Malate

Lu-Dotate

Lanreotide

Octreotide

 

Global Neuroendocrine Tumor Treatment Market, By Indication:

Gastrointestinal NET

Lung NET

Pancreatic NET

Others NET

 

Browse In-Depth Analysis Research Report @ https://www.coherentmarketinsights.com/market-insight/neuroendocrine-tumors-treatment-market-129

 

About Coherent Market Insights:

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

 

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Bone Degeneration Therapeutics Market to Experience Significant Growth By 2026

Bone degeneration is characterized by deterioration of articular cartilage covering the joints. Cartilage aids free movement of the joint without any resistance. Reduction in flexibility of the joint due to deterioration of cartilage leads to inflammation, compressed nerves, and pain. Aging is one of the natural causes of bone degeneration, which is also fueled by several conditions such as injuries, congenital disorders, diabetes, and obesity. Symptoms of degenerative bone disorders includes joint stiffness, radiating pain that initiates in the back and spreads through the extremities and causes joint inflammation.

 

Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/94

 

Osteoporosis – characterized by existence of porous bones may lead to fractures

 

There are two levels of bone loss that can result in an increased risk of fractures. Osteoporosis and osteopenia constitute two levels of bone loss. Osteopenia is considered as loss of bone material density, which indicates thinning of bones. Osteoporosis is a bone degeneration condition characterized by the existence of porous bones and it develops with time as bones slowly lose minerals, structure, and density, resulting in weaker bones. Eventually, osteoporosis leads to bent posture, cracked bones, and loss of height.

 

Excessive bone degeneration results in fragile bones that are highly susceptible to fracture. There are several tests such as bone densitometers and dual energy x-ray absorptiometry scans performed to determine the density of bones. Stimulation of soft tissues and cartilage repair with prolotherapy represents some of the ways of alleviating pain resulting from degenerative bone disorders.

 

Increasing diabetes incidence and rising obesity driving growth of the bone degeneration therapeutics market

 

Factors such as increased physical inactivity, rising obesity, and increasing rate of diabetes are fueling growth of the bone degeneration therapeutics market. According to World Health Organization (WHO) around 422 million people worldwide suffered from diabetes in 2014. Increasing number of diabetic patients is fueling growth of the bone degeneration therapeutics market.

 

Various products in research pipeline to augment the bone degeneration therapeutics market growth

 

Bone degeneration therapeutics market can be segmented by treatment and application. By treatment, the bone degeneration therapeutics market can be segmented into device, drug, and surgery. Braces or sleeves are used to relieve pain caused due to bone degeneration. These provide pain relief to orthopedic patients. By drug, the bone degeneration therapeutics market is segmented into cortisone or steroids, hyaluronic acid and platelet-rich plasma. Platelet-rich plasma is effective in alleviating pain resulting from arthritis of the knee. Some products such as PREOB and ALLOB (both from Bone Therapeutics SA) are in research pipeline. PREOB received orphan drug designation for osteonecrosis in March 2008 from the U.S. FDA. On the basis of surgery, the bone degeneration therapeutics market is classified as arthroscopy, high tibial osteotomy, and knee replacement. By application, the bone degeneration therapeutics market can be segmented as osteoporosis, osteopenia, and spinal fusion.

 

Bone degeneration market: Key players

 

Amgen, Inc., Fate Therapeutics, Inc., Bone Therapeutics SA, Juventus Therapeutics, Inc., Kaken Pharmaceutical Co., Ltd., Regenexx, and Se-cure Pharmaceuticals, Ltd. are some of the companies involved in development of bone degeneration therapeutic products. Regenexx stem cell and platelet-rich plasma procedures are advanced regenerative injection treatment used to treat knee pain due to arthritis, ligament injuries, and other degenerative conditions.

 

Browse Research Report @ https://www.coherentmarketinsights.com/ongoing-insight/bone-degeneration-therapeutics-market-94

 

About Coherent Market Insights:

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

 

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Latin America Bone Graft and Substitutes Market is Booming Worldwide till 2026

A bone graft repairs and rebuilds diseased bone and transplants bone tissues of the hips, knees, spine, and various other bones in the body. Moreover, it repairs bone loss caused by fractures and cancers. The body accepts the newly implanted graft and provides a framework for growth of new living bone. Bone grafts can be obtained either from the patient’s own body, a donor or can be entirely man-made from natural or synthetic materials. Autografts and allograft are the most common types of bone grafts. In allograft, bone is obtained from a deceased donor or a cadaver that is sterilized and stored in the tissue or bone banks. In autografts, bone is obtained from the patient’s own body parts such as ribs, pelvis, wrist, and hips. Furthermore, bone graft substitutes made up of materials such as ceramics and polymers are gaining preference. This is owing to osteoconductive and osteogenerative properties and easy availability of these grafts.

 

Get the inside scoop of the Sample report @ https://www.coherentmarketinsights.com/insight/request-sample/2644

 

Market Dynamics

 

Latin America bone graft and substitutes market is expected to witness significant growth over the forecast period, owing to increasing adoption of new technologies by manufacturers to develop novel bone graft substitutes. For instance, in March 2015, Osiris Therapeutics, Inc., a company based in Columbia, Maryland, introduced BIO4. BIO4 is a viable bone matrix containing endogenous bone forming cells including mesenchymal stem cells, osteoprogenitor cells, osteoblasts, osteoinductive, and angiogenic growth factors. BIO4 has all four characteristics involved in bone repair and regeneration including osteoconductive, osteoinductive, osteogenic, and angiogenic characteristics. It is a safe alternative to bone autograft that minimizes the potential for harvest site co-morbidities.

 

The Latin America bone graft and substitutes market was valued at US$ 116.8 million in 2018, and is expected to witness a CAGR of 5.6% during the forecast period (2018– 2026).

 

Latin America Bone Graft and Substitutes Market – Country-Wise Analysis

 

On the basis of country-wise segmentation, Latin America bone graft and substitutes market is divided into Colombia, Peru, Chile, and the rest of Latin America.

 

Colombia is projected to witness significant growth in Latin America bone graft and substitute market, owing to growing healthcare sector in the country. According to the World Health Organization (WHO), Colombia has the best and high quality healthcare system among all the Latin American countries. Moreover, WHO has ranked Colombia’s healthcare system at 22nd position out of all 191 countries across the world.

 

Latin America Bone Graft and Substitutes Market- Competitive Landscape

 

Key players operating in Latin America bone graft and substitutes market include, RTI Surgical, Inc., NuVasive, Inc., Exactech, Inc., Medtronic Plc., LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, Johnson & Johnson, Orthofix International N.V., Ace Surgical Supply Co., Inc., and Novabone Product, LLC

 

Detailed Segmentation:

 

Latin America Bone Graft and Substitutes Market , By Product Type:

Bone Graft

- Allografts

- Xenografts

Bone Graft Substitutes

- Ceramics

- Composites

- Polymers

- Bone Morphogenetics Proteins

- Others

 

Latin America Bone Graft and Substitutes Market , By Application:

Spinal Fusion

Dental Bone Grafts

Craniomaxillofacial

Joint Reconstruction

Trauma

 

Browse In-Depth Analysis Research Report @ https://www.coherentmarketinsights.com/market-insight/latin-america-bone-graft-and-substitutes-market-2644

 

About Coherent Market Insights:

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

 

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Tissue Plasminogen Activator Market – Global Growth Forecast Up To 2026

Tissue plasminogen activator (tPA) is an enzyme associated with the disintegration of blood clots. It is a serine protease present in endothelial cells. With the help of serine protease, the conversion of plasminogen to plasmin is catalyzed. Serine protease is a major enzyme for clot disintegration.

 

tPA is also be produced by using recombinant technology techniques known as recombinant tissue plasminogen activator (rtPA). Specific rtPAs are tenecteplase, alteplase, and reteplase. These enzymes are used in clinical treatment of thrombotic stroke or embolic stroke. tPA is a drug that dissolves blood clots. It is a thrombolytic agent which can be administrated into the veins.

 

Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/2469

 

Global Tissue Plasminogen Activator Market: Drivers

 

Tissue plasminogen activator is the first and only drug approved by the FDA in 1996 for the treatment of acute ischemic stroke. Increasing incidences of stroke has boosted the tissue plasminogen activator market size. According to John Hopkins Medicines (JHM) in the U.S., around 795,000 people in the U.S. suffer from stroke per year, as reported in 2014. According to the World Health Organization (WHO), stroke is the second leading cause of death and the third leading cause of disability, worldwide, as reported in 2012. This is one of the major factors driving the tissue plasminogen activator market growth.

 

Global Tissue Plasminogen Activator Market: Regional Analysis

 

North America is the leader in the global tissue plasminogen activator market, owing to rising awareness about stroke and huge spending on treatment of stroke. For instance, in 2017, the American Heart Association (AHA) recorded stroke costs as US$ 34 billion in the U.S. every year, which includes medicines for the treatment of stroke and cost of health care services.

 

Asia pacific is the fastest growing region in the tissue plasminogen activator market, owing to increasing demand drug coupled with rising stroke incidences in the region. According to WHO, Indonesia, Philippines, China, and India have highest rates of stroke, which is 186.3, 134.7, 128, and 71.5, respectively, as recorded in 2017.

 

Global Tissue Plasminogen Activator Market: Competitive Landscape

 

Key players operating in the global tissue plasminogen activator market include Bayer AG, Abcam, Calbiochem, Merck & Company, Roche, Sekisui Diagnostics, Genentech, Sigma-Aldrich, Taj Pharmaceuticals, and Cadila Healthcare Ltd.

 

Global Tissue Plasminogen Activator Market: Taxonomy

 

The global tissue plasminogen activator market is segmented on the basis of dosage, route of administration, application, and region.

 

By Route of administration:

 

Intravenous

Regional intra-arterial

 

By Application:

 

Blood clots

Pulmonary embolism

Myocardial infarction

Stroke

 

For More Information, Browse Complete Report Here: https://www.coherentmarketinsights.com/ongoing-insight/tissue-plasminogen-activator-market-2469

 

About Coherent Market Insights:

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

 

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Stem Cell Cartilage Regeneration Market Upcoming Trends Analysis Till 2026

In cartilage regeneration, stem cells have the potential for multiple differentiation and self-replication, making it an ideal choice for use as seed cells. Growing regenerative medicine industry and increasing demand for stem cells in the development of various types of cell therapies are expected to drive growth of the market over the forecast period. Mesenchymal stem cells are the most widely applied stem cells in the field of cartilage regeneration.

 

Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/2448

 

Market Dynamics

 

Growing osteoarthritis incidence among the global population is supporting the adoption of stem cell cartilage regeneration therapy. For instance, according to November 2017, Arthritis Foundation data findings, with the increase in global geriatric population, degenerative disease disorders such as osteoarthritis will impact at least 130 million individuals around the globe by 2050.

 

Furthermore, various government agencies are focusing on policies to enhance adoption of stem cell therapies, which is expected to drive growth of stem cell cartilage regeneration market in the near future. For instance, in December 2016, the 21st Century Cures Act (Cures Act) was signed into law by the U.S. FDA, thereby allowing legislation for an expedited approval path for cellular medicines designated as regenerative medicine advanced therapies (RMATs) to patients who are in need of it.

 

Stem Cell Cartilage Regeneration Market - Regional Insights

 

On the basis of region, the global stem cell cartilage regeneration market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be the most conducive region for growth of the stem cell cartilage regeneration market over the forecast period, due to high presence of key players in the region. Key players such as Vericel Corporation, Osiris Therapeutics, among others are focusing on various growth strategies such as gaining regulatory product approvals and launching innovative stem cell based cartilage regeneration products and technologies in the market.

 

Stem Cell Cartilage Regeneration Market - Competitive Landscape

 

Key players operating in the global stem cell cartilage regeneration market include Theracell Advanced Biotechnology Ltd., Orthocell Ltd., Xintela AB, CellGenix GmbH, Merck KGaA, Osiris Therapeutics, Inc., BioTissue SA, and Vericel Corporation.

 

Detailed Segmentation:

 

Global Stem Cell Cartilage Regeneration Market, By Stem Cell Type:

Hematopoietic Stem Cells (HSCs)

Pluripotent Stem Cells (iPSC/ESCs)

Mesenchymal Stem Cells (MSCs)

 

Global Stem Cell Cartilage Regeneration Market, By Treatment:

Microfracture

Osteochondral Transplant

Autologous Chondrocyte Implantation

Stem Cell Injections

 

For More Information, Browse Complete Report Here: https://www.coherentmarketinsights.com/market-insight/stem-cell-cartilage-regeneration-market-2448

 

About Coherent Market Insights:

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

 

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Nerve Biologic Products Market 2018 | Scope of Current and Future Industry 2026

Nerve biologic products include artificial nerve conduit, nerve graft, nerve wraps, or nerve capping devices used for guiding axonal regrowth to facilitate nerve regeneration. These devices are majorly used in clinical treatments for nerve injuries. Nerve biologic products are commonly used for complex suturing, for instance suturing of two ends of a separated nerve that needs rigid process. The scaffold material used for generating nerve biologic products is either from synthetic or biological origin. The nerve biologic products are manufactured from various biocompatible products such as polysialic acid (PSA), collagen type I/III, spider silk fiber, silkworm silk fibroin, chitosan, aragonite, and alginate.

 

Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/2265

 

Nerve Biologic Products Market Drivers

 

Advancements in research and development for developing innovative technology for nerve biologic products are expected to drive growth of the nerve biologic product market. For instance, in February 2015, researchers from the University of Sheffield developed a device, 3D-printed nerve guidance conduit (NGC). NGC is a network of miniature tubes, which guide injured nerve ends towards each other, thereby enabling them to repair naturally. The device uses computer-aided design (CAD), which can be modified for any type of nerve damage or even adapted for joint specific nerves of patient.

 

Furthermore, in June 2016, Polyganics, a medical device manufacturing company, received the CE mark for Neurocap, its nerve capping device. Neurocap is an absorbable implant for treatment and reduction of symptomatic neuroma in peripheral nerves. The device was cleared for sales in the U.S. in January 2016.

 

Nerve Biologic Products Market – Regional Analysis

 

On the basis of region, the global nerve biologic products market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

 

Based on region, North America is expected to hold lead position in the global nerve biologic products market during the forecast period, owing to rising number of peripheral nerve injuries in the U.S. For instance, according to Proceedings of the National Academy of Sciences of the U.S. study in June 2017, over 250,000 people from the U.S. suffers from peripheral nerve injury annually.

 

Key Players

 

Key players operating in the global nerve biologic products market include, Stryker, AxoGen, Inc., Integra LifeSciences, Collagen Matrix, Inc., Polyganics, Checkpoint Surgical Inc., and TEXAS PHARMACUETICAL PVT LTD.

 

Nerve Biologic Products Market – Taxonomy

 

By Product Type:

 

Nerve Wraps

Nerve Grafts

Nerve Conduit

Nerve Capping

 

By Application:

 

Nerve Grafting

Direct Nerve Repair/ Neurorrhaphy

Dural Defects

Peripheral Nerve Injuries

 

Browse In-Depth Analysis Research Report @ https://www.coherentmarketinsights.com/ongoing-insight/nerve-biologic-products-market-2265

 

About Coherent Market Insights:

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

 

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Recombinant Therapeutic Antibodies and Proteins Market Growth Outlook to 2026

Therapeutic proteins are engineered in the laboratory for pharmaceutical use, including non-covalent binders. These proteins are highly effective and serve as modernized treatment for rare as well as chronic diseases. Protein therapeutics offer custom-made treatment approach by supporting a specifically targeted therapeutic process by compensating the deficiency of an essential protein. Recombinant proteins have gained significant traction for therapeutic applications and the number of proteins either launched or approved into clinical trials has continually increased over the past two decades. According to the National Center for Biotechnology Information (NCBI) data of 2017, the U.S. Food and Drug Administration (FDA) approved over 140 recombinant therapeutic proteins for human use and several hundred are currently in development. Majority of these proteins are recombinant monoclonal antibodies.

 

Free Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/1981

 

The global recombinant therapeutic antibodies and proteins market size was valued at US$ 91.2 billion in 2017, and is expected to witness a robust CAGR of 12.2% over the forecast period (2018 – 2026).

 

Integration of novel approaches and strategies to modify protein drug products is an important aspect. Advancements in recombinant protein technologies have allowed drug manufacturers and developers to adjust required functional characteristics of proteins of interest while maintaining product efficacy and safety.

 

Various recombinant technologies are currently in use to increase the half-life, functionality, and targeting of novel therapeutic protein drugs and increase product purity and volume. For instance, protein conjugation and derivatization methods, including albumin-fusion15, PEGylation and Fc-fusion are currently being used to extend a drug’s circulating half-life.

 

Increasing government support for novel drug development is expected to augment the market growth

 

Governments are supporting research and development of novel products due to rapid advancements in biomedical science and technology to address unmet medical needs. In 2012, the Food and Drug Administration Safety and Innovation Act (FDASIA) was signed to provide the FDA with the capability to establish breakthrough therapy designation (BTD), a new program within the Expedited Programs for Serious Conditions. It was designed to be available for drugs designed to treat a serious condition and that have been shown to exhibit initial clinical evidence of significant improvement over existing treatments.

 

Major players operating in the global recombinant therapeutic antibodies and proteins market include Abbott, Amgen Inc., Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer Inc., and Sanofi S.A.

 

Detailed Segmentation:

 

Global Recombinant Therapeutic Antibodies and Proteins Market, By Drug Class:

Plasma Protein

Growth Factors

Fusion Proteins

Monoclonal Antibodies

Hormones

Enzyme

Coagulation Factors

Others

 

Global Recombinant Therapeutic Antibodies and Proteins Market, By Application:

Oncology

Hematology

Immunology

Endocrinology

Infectious Disease

Cardiovascular Diseases

Others

 

Find the comprehensive research report here with a single click: https://www.coherentmarketinsights.com/market-insight/recombinant-therapeutic-antibodies-and-proteins-market-1981

 

About Coherent Market Insights:

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

 

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Remicade Biosimilars Market Growth Outlook and Opportunity Analysis to 2026

Biosimilar refers to biotherapeutic product that is similar in terms of quality, efficacy, and safety to an existing licensed reference therapeutic drug. Biological products are the fastest growing class of therapeutic products, as they offer additional treatment options and help in lowering healthcare costs. Biosimilars are almost identical copies of the originally approved drugs and can be manufactured only when the patent for the original innovator drug expires. These products are highly sensitive to smallest changes in manufacturing procedure, as these drugs possess high molecular complexity. Remicade (Infliximab) refers to a chimeric monoclonal antibody biologic licensed by U.S. FDA in 1998, as an innovative product indicated for the treatment of Crohn’s disease in adults and children. The monoclonal antibody drug was first developed in partnership by Janssen Biotech, Inc. and Merck & Co. The Remicade was later approved for its use in the treatment of ulcerative colitis, plague psoriasis, rheumatic arthritis, and spinal psoriatic arthritis in combination with methotrexate. Later, various pharmaceutical manufacturers developed biosimilars to infliximab, which lowered market share of Remicade due to cost-effective prices.

 

Free Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/1769

 

Market Dynamics

 

Increasing incidence of autoimmune diseases such as plaque psoriasis and rheumatoid arthritis are expected to drive growth of the Remicade biosimilar market size. According to the American Autoimmune Related Disease Association, around 50 million American suffered from autoimmune diseases in the U.S. in 2017. Moreover, faster reaction rates of these biosimilars due to their availability in the form of intravenous mode of administration is further expected to increase the adoption of Remicade biosimilar over the forecast period. Furthermore, patent expiry of the branded versions is expected to increase the number of biosimilars for its branded counterparts thereby increasing the demand for Remicade biosimilar. However, stringent regulatory guidelines for development of these biosimilars as well as side effects of these drugs leading to risk of hospitalization are expected to restrain growth of the global Remicade biosimilar market.

 

Regional Insights

 

On the basis of region, the global Remicade biosimilar market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Europe holds a dominant position in the global Remicade biosimilar market and is expected to retain its dominance over the forecast period, owing to the presence of top market players in the region, rapid entry of biosimilars in the European market as well as high adoption rate due low price of the biosimilars. For instance, in 2018, Sandoz, a Novartis division received European Commission (EC) approval for Zessly (infliximab) a remicade biosimilar for use in Europe. The successive research and speedy approvals by the U.S. regulatory authorities for market entry of biosimilars in North America is expected to drive growth of the market over the forecast period. For instance, in December 2017, Pfizer, Inc. received the U.S. FDA approval for second biosimilar, Ifixi to Janssen’s blockbuster drug Remicade to treat rheumatoid arthritis.

 

Competitive Landscape

 

Key players operating in the global remicade biosimilar market include Janssen Biotech, Inc., Merck and Company, Inc., Alvogen, Pfizer, Inc., Celltrion, Nippon Kayaku, Napp Pharmaceuticals, and others. Market players are focused on introducing maximum number of biosimilar for multiple indications to retain their position in the global market. For instance, in July 2017, Merck & Company, Inc. in collaboration with Samsung Bioepis introduced Renflexis (infliximab-abda), a biosimilar to Remicade for the treatment of moderate to severe Crohn’s disease, active ulcerative colitis, rheumatoid arthritis, and other few disease indications.

 

The increasing prevalence of rare cancer in patients owing to oncological diseases segment to dominate in the orphan drugs market

 

The global orphan drugs market is segmented on the basis of disease, by product type and by region

 

On the basis of disease type,

 

Hematologic and Immunologic diseases

Infectious diseases

Metabolic diseases

Neurologic diseases

Oncologic diseases

Other orphan diseases

 

On the basis of product type,

 

Biological orphan drugs

Non-biological orphan drugs

 

Browse In-Depth Analysis Research Report @ https://www.coherentmarketinsights.com/ongoing-insight/remicade-biosimilars-market-1769

 

About Coherent Market Insights:

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

 

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Enzyme Replacement Therapy Market Strategies and Forecasts to 2026

Enzyme replacement therapy involves intravenous administration of enzymes in order to correct the deficiency of enzymes that causes a specific disease condition called lysosomal storage disease. Enzyme replacement therapy is used in Fabry Disease, Gaucher disease, lysosomal acid lipase deficiency, mucopolysaccharidosis, Hunter syndrome, and Pompe disease. Enzymes are obtained from sources such as human cells, animal cells, and recombinant DNA technology. Enzyme replacement, although does not provide permanent cure, helps prevents permanent damage to the body caused due to deficiency of a specific enzyme. Treatment consists of weekly or monthly doses depending upon the disease. For instance, in order to address enzyme deficiency in Gaucher disease, modified version of glucocerebrosidase is administered intravenously every two weeks. Enzyme replacement is associated with fewer side effects than other treatment methods. However, enzyme replacement therapy may be inconvenient for some patients such as children and geriatric population due to intravenous administration. It may result in local infusion reaction or hypersensitive reactions in the form of local rash, fever, edema, bronchospasm or hypotension.

 

Free Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/1752

 

Market Dynamics

 

Although lysosomal storage disease is a rare disorder, a significant number of people are affected with this disease. According to study published in Molecular Genetics and Metabolism Reports in December 2017, lysosomal storage disease has incidence rate of 1 in 4000 to 1 13,000 live births. Lysosomal storage disease consists of 60 genetic abnormalities with problematic enzyme function. Being an orphan disease condition, regulatory agencies offer the benefit of rapid approval and ease in approval process. This in turn, is expected to expand the overall enzyme replacement therapy market with introduction of new therapies by various key players. For instance, in November 2017, The FDA approved Mepsevii (vestronidase alfa), which is first authorized treatment for pediatric and adult patients suffering from an inherited metabolic condition called mucopolysaccharidosis type VII (MPS VII). FDA granted Mepsevii with fast-track approval and orphan drug status to incentivize the development. Financial help by NGOs such as National Gaucher Society help patient receive enzyme replacement therapy that are costly.

 

Regional Insights

 

On the basis of geography, the global enzyme replacement therapy market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to lead the market during forecast period, followed by Europe. According to study published in journal Hematology, in March 2017, incidence of Gaucher Disease in the general population varied from 0.39 to 5.80 per 100?000, and its prevalence varied from 0.70 to 1.75 per 100?000. Ease in access and government support for research and development is expected to aid growth of the enzyme replacement therapy market.

 

Competitive Landscape

 

Key players operating in the global enzyme replacement therapy market include Shire plc, Amicus Therapeutics, Genzyme Corporation, Pfizer Inc., BioMarin Pharmaceutical, Inc., Sigma-Tau Pharmaceuticals, Inc., Essential Pharmaceuticals Limited, Merck KGa, and AbbVie Inc.

 

Market Taxonomy

 

On the basis of enzyme type, the global enzyme replacement therapy market is segmented into -:

 

Agalsidase Beta

Velaglucerase Alfa

Imiglucerase

Taliglucerase

Alglucosidase Alfa

Laronidase

Idursulfase

Galsulfase

Pegademase

Others

 

On the basis of indication, the global enzyme replacement therapy market is segmented into -:

 

Fabry Disease

Gaucher Disease

Pompe Disease

Scheie Syndrome

Hunter Disease

Maroteaux-Lamy Syndrome

Others

 

Browse In-Depth Analysis Research Report @ https://www.coherentmarketinsights.com/ongoing-insight/enzyme-replacement-therapy-market-1752

 

About Coherent Market Insights:

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

 

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Stem Cell Assay Market: Evolving Technology, Trends and Industry Analysis 2026

Stem cells are basic form of biological cells, which can differentiate into other types of cells and can produce more of the same type of stem cells. There are two types of stem cells, which include embryonic stem cells, and adult stem cells. These cells are present in areas in the body such as bone marrow, adipose tissue, and blood. Stem cells are also taken from umbilical cord blood. The stem cell population in the body is maintained through two processes, which include obligatory asymmetric replication and stochastic differentiation. Stem cells play an important role in the natural healing process of the body and introduction of stem cells has shown positive results in the treatment of many diseases such as cancer. The significance of stem cell assays lies in the fact that they are used for various processes such as viability or cytotoxicity studying, isolation and purification of stem cells, cell identification, cell proliferation, and cell differentiation for research purposes. In the case of stem cell transplant, initially, the embryonic stem cells are specialized into necessary adult cell type. Then, these cells are used to replace the tissue that is damaged due to any disease or injury. Commercially available stem cell assays include NSC ICC Kit, Stem Cell Pluripotency Array, TaqMan Array Mouse Stem Cell Pluripotency Panel, and TaqMan iPSC Sendai Detection Kit.

 

Ask Sample Copy of Research @ https://www.coherentmarketinsights.com/insight/request-sample/1632

 

Stem Cell Assay Market Drivers

 

Rising prevalence of various diseases such as cancer and cardiovascular diseases, and potential of stem cell therapy in the management of these diseases is expected to drive growth of the stem cell assay market over the forecast period. According to the American Cancer Society, in 2017, cancer was the second most common cause of death in the U.S., which accounted for nearly 1 out of every 4 deaths. Novel therapies such as stem cell transplant and stem cell therapy could potentially improve medical outcomes of chronic diseases. Also, pure stem cells are required to conduct research for various purposes. Stem cell transplant could replace the neurons damaged by spinal cord injury, stroke, and Alzheimer’s disease. These factors are expected to drive growth of the stem cell assay market over the forecast period. Moreover, organizations such as California’s Stem Cell Agency is indulged in the development of new stem cell based therapies for chronic diseases such as cancer and rare diseases.

 

Stem Cell Assay Market Insights

 

North America and Europe are expected to witness significant growth in the market over the forecast period. This is owing to presence of key manufacturers and researchers of stem cell based therapies in these regions. Moreover, manufacturers such as ThermoFisher Scientific, and Agilent Technologies, Inc. providing stem cell assay are present in North America region, which fuel growth of the market. Asia Pacific region is expected to show significant growth over the forecast period, as researchers from China and Japan are working on stem cell based therapies. For instance, in 2017, clinical trials of embryonic stem cells were launched in China for Parkinson’s disease.

 

Stem Cell Assay Market Competitive Landscape

 

Key players operating in the global stem cell assay market include Merck & Co., Thermo Fisher Scientific, GE Healthcare, Agilent Technologies, Bio-Rad Laboratories, Promega Corporation, Cell Biolabs, PerkinElmer, Miltenyi Biotec, HemoGenix, Bio-Techne Corporation, STEMCELL Technologies, and Cellular Dynamics International.

 

Stem Cell Assay Market Taxonomy-

 

The global stem cell assay market is segmented on the basis of product type, cell type, process, application, and geography.

 

By Product Type-

 

Instruments

Reagents & Kits

 

By Application -

 

Research

Drug Discovery & Development

Regenerative Medicine

 

Find the comprehensive research report here with a single click: https://www.coherentmarketinsights.com/ongoing-insight/stem-cell-assay-market-1632

 

About Coherent Market Insights:

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

 

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Vascular Endothelial Growth Factor Antibodies Market Drivers, Insights Analysis to 2026

Vascular Endothelial Growth Factor (VEGF) is a signal protein that helps in the formation of new blood vessels through a process known as angiogenesis. Vascular endothelial growth factor is a part of several pathological processes and researches are often carried out for the development of novel therapies using these factors for diseases such as cancer. Normal functions of vascular endothelial growth factor includes embryonic development, formation of new blood vessels, and as a bypass for a blocked vessel. However, overexpression of VEGF often culminates into fatal disease such as cancerous cells. As solid tumors require additional blood supply in order to keep functioning, the overexpression of VEGF serves that purpose through angiogenesis. VEGF family has five members such as VEGF-A, VEGF-B, VEGF-C, VEGF-D, and Placenta Growth Factor (PGF). Out of these growth factors, VEGF-A is responsible for angiogenesis and processes associated with endothelial cells. VEGF-A binds to VEGF receptors on the endothelial cells, which triggers a tyrosine kinase pathway leading to angiogenesis. VEGF-A has been found to be associated with poor prognosis in various cancers, diabetic retinopathy, and age-related macular degeneration. Therapeutic agents are developed to inhibit the transduction pathways of vascular endothelial growth factor (VEGF). Drugs such as monoclonal antibodies against VEGF and tyrosine kinase inhibitors inhibit the angiogenesis process and disease progression.

 

Free Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/1614

 

Vascular Endothelial Growth Factor (VEGF) Antibodies Market Drivers

 

Rising prevalence of diseases such as cancer and macular degeneration is expected to boost growth of the market over the forecast period. According to the American Cancer Society, in 2017, cancer was the second most common cause of death in the U.S., which accounts for nearly 1 out of every 4 deaths. Novel therapies such as monoclonal antibodies and angiogenesis inhibitors are highly specialized targeted therapies, which directly targets the cancerous cells. The preference for targeted therapies is rising, owing to the advantages (lesser side effects) offered by targeted therapies over conventional therapies such as chemotherapy. Furthermore, robust pipeline of VEGF antibodies is expected to boost the market growth over the forecast period. For instance, Brolucizumab (Alcon) is in phase 3 clinical trials, Abicipar (Allergan Plc) is in phase 3 trials, and RG7716 (Genentech) is in phase 2 trials, all indicated for age-related macular degeneration.

 

Vascular Endothelial Growth Factor (VEGF) Antibodies Market Insights

 

On the basis of region, North America and Europe are expected to show significant growth in the vascular endothelial growth factor antibodies market over the forecast period. North America has the presence of leading manufacturers who are indulged in research and development of these therapies. Manufacturers such as Novartis (Europe) and Genentech have these therapies in pipeline and are expected to enter into the market over the forecast period. Asia Pacific region is expected to show modest growth, owing to high costs of these therapies and fairly low availability overall the region. Sophisticated insurance facilities such as Medicaid and Medicare are not present in the developing economies due to which patients cannot afford costly medical treatment in these regions. However, insurance facilities are expected to drive growth of the market in North America.

 

Key players operating in the vascular endothelial growth factor (VEGF) antibodies market include Genentech, Inc., Novartis, Exelixis, Inc., Eli Lilly and Company, Bayer Pharma AG, Regeneron Pharmaceuticals, Inc., Valeant Pharmaceuticals, Ceres Oncology Pty Ltd, and ThromboGenics, Inc.

 

Vascular Endothelial Growth Factor (VEGF) Antibodies Market Taxonomy

 

The global vascular endothelial growth factor (VEGF) antibodies market is segmented on the basis of drug, route of administration, application, distribution channel, and geography.

 

By Drug -

 

Avastin

Tecentriq

Cometriq

Eylea

Jetrea

Cyramza

Macugen

Lucentis

Others

 

By Application-

 

Cancer

Ophthalmology

Others

 

Browse In-Depth Analysis Research Report @ https://www.coherentmarketinsights.com/ongoing-insight/vascular-endothelial-growth-factor-antibodies-market-1614

 

About Coherent Market Insights:

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

 

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Anti-body Coupled T Receptor Therapy Market Growth Analysis and Trends to 2026

Anti-body coupled T receptor (ACTR) therapy is kind of immunotherapy used to treat cancer in which body’s own immune response is utilized to act on cancerous cell. Anti-body coupled T receptor therapy utilizes T cells from body, engineered it to express specific T cell receptor, multiplying it in lab and then administering it along with targeting antibodies. The advantage in this approach is, that these T cells do not attack normal antigens from blood circulation but attack only antigens attached to the cancerous cells. This is possible as tumor specific monoclonal antibodies are given together with ACTR T cells. ACTR therapy is cost effective as it can be used in various cancer therapy. Also, greater therapeutic benefit with minimum side effects can be possible by adjusting the amount of targeting antibody which is essential for activation of the ACTR T cells.

 

Get Free PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1600

 

Rising incidence of cancer and new products to be launched in future to drive the market for anti-body coupled T receptor therapy market.

 

According to World Health Organization (WHO), cancer is one of the leading non-communicable disease and second leading cause of death globally. As reported by International Agency for Research on Cancer (IARC) in 2012, there were 14.1 million new cases, 8.8 million deaths and 32.6 million people living with cancer worldwide. As per 2017 report by Leukemia and Lymphoma Society, U.S. alone is expected to have prevalence of 8,16,834 and 80,500 annual new cases of lymphoma. Therefore, such high number of cancer patient would propel the anti-body coupled T receptor therapy market.

 

ACTR therapy is better in its approach than other adoptive T cell transfer technologies such as CAR-T cell therapy. CAR-T therapy products such as Kymriah (Novartis AG) or Yescarta (Gilead Lifescience, Inc.) has side effects such as cytokine release syndrome, and neurological toxicity as discussed in their respective product literatures and other studies. ACTR therapy being specific in its action do not produce such side effects. This advantage would drive the anti-body coupled T receptor therapy market in future. Also CAR-T therapy has application in specific type of cancer such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, multiple myeloma whereas ACTR therapy has potential use even in solid tumorous cancer such as breast cancer, and neuroblastoma.

 

Cost of product can be a major concern. Kymriah which is a CAR-T therapy costs approximately US$ 4,75,000 per patient. Considering such high cost for CAR-T therapy it can be assumed that anti-body coupled T receptor therapy can also costs on similar line as it works in same segment of immuno oncology, which may limit the potential growth of anti-body coupled T receptor therapy market.

 

Strategic merger and acquisition amongst the companies to expand the market for anti-body coupled T receptor therapy.

 

Unum Therapeutics is currently the only company that is working actively in anti-body coupled T receptor therapy. It has several product in its pipeline, and they vary based on the technology used for expression of receptor in patients T cell such as mRNA or viral vector. There is also combination of different monoclonal antibodies to be used for coupling such as rituximab, and trastuzumab. In phase one clinical trial, rituximab coupled t receptor therapy found to produce desired therapeutic effects. Seattle Genetics, Inc. and Unum Therapeutics, Inc. in 2015 entered into a strategic collaboration and license agreement to develop and commercialize novel antibody-coupled T-cell receptor (ACTR) therapies for cancer. This collaboration would enable study of different combination of the tumor-specific monoclonal antibodies with T receptor and cater to patient specific treatment needs.

 

To know the latest trends and insights prevalent in the keyword market, click the link below: https://www.coherentmarketinsights.com/ongoing-insight/anti-body-coupled-t-receptor-therapy-1600

 

About Coherent Market Insights:

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

 

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Immune Repertoire Sequencing Market Growth Analysis and Opportunity 2018-2026

Immune repertoire sequencing is extensively used in biomarker discovery to improve the success rate and cost-effectiveness of rational drug development. For instance, in November, 2017, the Center for Commercialization of Cancer Immunotherapy (C3i) started offering T cell receptor-beta sequencing services in its Biomarker and Diagnostic unit in Canada. Increasing demand for personalized medicine, in turn, is expected to aid the immune repertoire sequencing market growth, as personalized medicine uses an individual’s genetic profile to guide decisions made in regard to the diagnosis, prevention, and treatment of diseases.

 

The global immune repertoire sequencing market size was valued at US$ 114.3 million in 2017, and is expected to witness a CAGR of 5.6% over the forecast period (2018 – 2026).

 

Free Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/1517

 

Increasing Research & Development and Demand for Genomic and Repertoire Sequencing-based Research is expected to Drive Growth of the Immune Repertoire Sequencing Market

 

Increasing research and development and launches of novel products by key players are expected to be the major driving force for global immune repertoire sequencing market growth in the near future. For instance, in 2016, ArcherDX, Inc. expanded its product portfolio with the launch of Archer Immunoverse immune repertoire sequencing assays at the American Society of Hematology (ASH). In 2017, ArcherDX, Inc. launched Archer Immunoverse B Cell Receptor (BCR) assays to characterize the human B cell repertoire.

 

According to a study published by Cold Spring Harbor Laboratory, in 2017, researchers from Stanford University applied immune repertoire sequencing to identify disease-related signatures in the immune systems of patients with systemic sclerosis-related pulmonary hypertension (SSc-PAH), a rare chronic autoimmune disease that affects the connective tissue. Therefore, increasing research on immune repertoire sequencing is expected to create a favorable environment for immune repertoire sequencing market growth in the near future.

 

Immune Repertoire Sequencing Market - Regional Insights

 

On the basis of region, the global immune repertoire sequencing market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global immune repertoire sequencing market during the forecast period, owing to high presence of key industry players in the region (including Illumina Inc., Thermo Fisher Scientific, Pacific Biosciences, and CD Genomics). These players are increasingly focusing on development of novel technologies for immune repertoire sequencing. For instance, in 2017, 10x Genomics Inc., U.S. based company, added B-Cell and 5’Unbiased Enrichment Kit to its chromium immune repertoire profiling solution or immune repertoire sequencing.

 

Immune Repertoire Sequencing Market - Competitive Landscape

 

Key players operating in the global immune repertoire sequencing market include Thermo Fisher Scientific, Inc., Illumina Inc., ArcherDX, Inc., Roche Holding AG, Pacific Biosciences, CD Genomics, Atreca, Inc., Adaptive Biotechnologies, Oxford Nanopore Technologies, Ltd., Qiagen N.V., Agilent Technologies, Inc., and Takara Bio, Inc.

 

Detailed Segmentation:

 

Global Immune Repertoire Sequencing Market, By Product Type:

Assay Kits

- T-Cell Receptor (TCR) Kits

- B-Cell Receptor (BCR) Kits

Instruments

 

Global Immune Repertoire Sequencing Market, By Application:

Cancer Immunotherapy

Biomarker Discovery

Autoimmune Diseases

Vaccine Development and Efficacy

Transplant Rejection and Tolerance

Infectious Diseases

Other Applications

 

Find the comprehensive research report here with a single click: https://www.coherentmarketinsights.com/market-insight/immune-repertoire-sequencing-market-1517

 

About Coherent Market Insights:

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

 

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Oncology Biosimilars Market – Size, Share, Outlook, and Opportunity Analysis 2018 - 2026

Biosimilar is a biological product that resembles a reference product and is not difference from the already approved reference product. These are relatively cheaper than branded or approved products. Several biologics for oncology have already lost their patents, and some are in its period of expiry. As more products are expected to lose patents, biosimilar is expected to gain popularity. Leading generic players such as Mylan N.V., Teva Pharmaceutical Industries Ltd, Allergan Plc, Sandoz (a Novartis International AG’s division) are expected to capitalize on these patent expiries and may establish themselves as dominating players in oncology biosimilars market.

 

Get Free PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1305

 

Rapid approval of biosimilars for oncology is expected to be a major driving factor for growth of the oncology biosimilars market over the forecast period

 

There was about a decade gap in approval of first biosimilars in two key markets, Europe and the U.S. First biosimilar was approved in 2006 in Europe, however, in the U.S. first product was approved in 2015. But since approving the first biosimilar, the FDA has approved five products in 2017. Out of these five biosimilars, two were approved for oncology. First, oncology biosimilar Mvasi (bevacizumab-awwb) received approval in September 2017, and second one, Ogivri (trastuzumab) was approved in December 2017. In Europe, both of the products have been approved, and Mvasi received approval from European Commission in January 2018.

 

Moreover, there are number of biosimilar application pending in the U.S. and Europe. For Herceptin (trastuzumab) alone, there are around four application pending in the FDA. These four application are from Amgen and Allergan, Celltrion and Teva, Pfizer, and Samsung Bioepis. Recent approval of products, and potential approval in next few years is expected to boost the market growth over the forecast period.

 

North America is expected to dominate the oncology biosimilars market over the forecast period

 

On the basis of region, oncology biosimilars market by Coherent Market Insights is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be the dominant market over the forecast period. U.S. FDA approved first biosimilar in 2015, almost a decade later than first biosimilar approval in Europe. However, since 2015, the number of approved products has increased rapidly. This is expected to be factor for growth of the market in North America. Moreover, currently there are number of products in pipeline, which may receive approval from the FDA over the forecast period. For instance, Pfizer Inc. — a U.S.-based company — has three biosimilar products (i.e. PF-05280014, PF-05280586 and PF-06439535) for oncology in Phase 3.

 

Key players operating in the global oncology biosimilars market include Amgen Inc., Allergan, Plc, Mylan N.V., Samsung Bioepis Co., Ltd., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Celltrion Healthcare, Novartis International AG, Biogen Idec, Inc., and Biocon Limited.

 

Oncology Biosimilars Market Taxonomy

 

By Cancer Type:

 

Lung Cancer

Colorectal cancer

Cervical Cancer

Breast Cancer

Kidney cancer

Stomach cancer

Brain Cancer

Others

 

By Product Type:

 

Monoclonal Antibody

Immunomodulators

Others

 

Browse In-Depth Analysis Research Report @ https://www.coherentmarketinsights.com/ongoing-insight/oncology-biosimilars-market-1305

 

About Coherent Market Insights:

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

 

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com